Aktuelle Neurologie, Inhaltsverzeichnis Aktuelle Neurologie 2013; 40(05): 285-286DOI: 10.1055/s-0033-1343236 Kompetenznetz Multiple Sklerose © Georg Thieme Verlag KG Stuttgart · New York Aktuelles aus der Forschung S. G. Meuth 1 Klinik für Allgemeine Neurologie, Department für Neurologie, Universitätsklinikum Münster , T. Korn 2 Neurologische Klinik und Poliklinik, Klinikum rechts der Isar, TU München › Institutsangaben Artikel empfehlen Abstract Artikel einzeln kaufen Volltext Referenzen Literatur 1 Zaguia F, Saikali P, Ludwin S et al. Cytotoxic NKG2C+ CD4 T Cells Target Oligodendrocytes in Multiple Sclerosis. Journal of Immunology 2013; 190: 2510-2518 2 Uzawa A, Mori M, Sawai S et al. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clinica Chimica Acta 2013; 421: 181-183 3 Ayzenberg I, Kleiter I, Schröder A et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013; 70: 394-397 4 Jun JE, Wilson LE, Vinuesa CG et al. Identifying the MAGUK protein Carma-1 as a central regulator of humoral immune responses and atopy by genome-wide mouse mutagenesis. Immunity 2003; 18: 751-762 5 Brüstle A, Brenner D, Knobbe CB et al. The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells. J Clin Invest 2012; 122: 4698-4709
